Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv., 2025, 15, 231–243
Abstract
This comment addresses significant limitations in the study by Lu et al. (RSC Adv., 2025, 15, 231–243), which investigates the anticancer activity of quinoline-based dihydrazone derivatives. It highlights the misidentification and contamination of cell lines used in the research, specifically BGC-823, BEL-7402, and HL-7702, which are derived from HeLa cells rather than being true representations of human gastric cancer, human hepatoma, or normal liver cells. The letter emphasizes the need for caution when interpreting findings related to cell state (normal versus tumor) due to these discrepancies, as they may significantly affect conclusions regarding efficacy and safety profiles in anticancer research.
Please wait while we load your content...
